Nephrogenic systemic fibrosis (NSF) is a rare, potentially fatal condition caused by iatrogenic gadolinium administration in patients with acute kidney injury or stage 4 or 5 chronic kidney disease (CKD), defined as an estimated glomerular filtration rate (eGFR) of less than 30 mL/min/1.73 m
2.
1-4 After more than 500 cases of NSF were reported from 1997 to 2007, regulations were adopted to prevent NSF.
5 In 2007, the US Food and Drug Administration mandated a black box warning advising avoidance of all gadolinium-containing contrast agents (GBCA) in at-risk patients.
5 The label was updated in 2010 to contain recommendations for health care professionals regarding kidney function screening, use of lower-risk GBCAs, and decreasing GBCA dose.
6 Such recommendations informed hospital policies and were successful in effectively eliminating the disease.
7-9 However, they also resulted in denial or delay of clinically indicated, contrast-enhanced magnetic resonance imaging (MRI) in patients with severe kidney disease, resulting in the undermeasured indirect harms of misdiagnosis and delayed diagnosis.
10 In addition, the guidelines were applied to all GBCAs regardless of gadolinium-chelate lability or association with NSF.
11,12